Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Research & Development (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Research & Development readings, the most recent being $74.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Research & Development fell 2.78% year-over-year to $74.2 million, compared with a TTM value of $295.9 million through Dec 2025, down 9.68%, and an annual FY2025 reading of $295.9 million, down 9.68% over the prior year.
  • Research & Development hit $74.2 million in Q4 2025 for Apellis Pharmaceuticals, up from $68.2 million in the prior quarter.
  • The five-year high for Research & Development was $110.0 million in Q1 2023, with the low at $67.0 million in Q2 2025.
  • Median Research & Development over the past 5 years was $85.6 million (2024), compared with a mean of $85.5 million.
  • The sharpest move saw Research & Development surged 55.32% in 2021, then plummeted 30.32% in 2023.
  • Year by year, Research & Development stood at $78.2 million in 2021, then increased by 27.17% to $99.4 million in 2022, then plummeted by 30.32% to $69.3 million in 2023, then increased by 10.21% to $76.4 million in 2024, then fell by 2.78% to $74.2 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $74.2 million, $68.2 million, and $67.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.